Ajinomoto Co., Inc. (TYO: 2802)

Japan flag Japan · Delayed Price · Currency is JPY
5,473.00
+31.00 (0.57%)
Sep 9, 2024, 3:15 PM JST
-10.21%
Market Cap 2.77T
Revenue (ttm) 1.47T
Net Income (ttm) 83.87B
Shares Out 505.34M
EPS (ttm) 162.38
PE Ratio 33.70
Forward PE 26.42
Dividend 40.00 (0.74%)
Ex-Dividend Date Sep 27, 2024
Volume 918,200
Open 5,350.00
Previous Close 5,442.00
Day's Range 5,333.00 - 5,477.00
52-Week Range 4,886.00 - 6,390.00
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Nov 7, 2024

About Ajinomoto Co.

Ajinomoto Co., Inc. engages in the seasonings and foods, frozen foods, and healthcare and other businesses in Japan and internationally. The Seasonings and Foods segment offers sauces and seasoning products under the AJI-NO-MOTO, HON-DASHI, Cook Do, Ajinomoto KK Consommé, Pure Select Mayonnaise, Ros Dee, Masako, Aji-ngon, Sazón, Sajiku, and CRISPY FRY names; and solutions and ingredients for foodservice and processed food manufacturers, processed foods, and restaurants, as well as industrial, retail, and other applications. This segment also pr... [Read more]

Industry Packaged Foods
Founded 1909
Employees 34,862
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 2802
Full Company Profile

Financial Performance

In 2023, Ajinomoto Co.'s revenue was 1.44 trillion, an increase of 5.89% compared to the previous year's 1.36 trillion. Earnings were 87.12 billion, a decrease of -7.38%.

Financial Statements

News

Ajinomoto Co., Inc. (AJINY) Q1 2024 Earnings Call Transcript

Ajinomoto Co., Inc. (OTCPK:AJINY) Q1 2024 Earnings Conference Call August 5, 2024 4:00 AM ET Company Participants Masataka Kaji - GM Taro Fujie - Director, Representative Executive Officer, President ...

4 weeks ago - Seeking Alpha

Ingredients Pioneer Ajinomoto Health & Nutrition Partners with Shiru, Leveraging AI to Discover and Develop Sweet Proteins for Use in Beverages and Specialty Products

BERKELEY, Calif.--(BUSINESS WIRE)--Ajinomoto Health & Nutrition Partners with Shiru, Leveraging AI to Discover and Develop Sweet Proteins for Use in Beverages and Specialty Products.

5 weeks ago - Business Wire

Ajinomoto Co., Inc. Enhances StemFit iPS Cell Expansion Medium

Leveraging Advanced Manufacturing and Strict Quality Control for Superior Performance in Cellular Medicine TOKYO , March 26, 2024  /PRNewswire/ -- Today, Ajinomoto Co., Inc. ("Ajinomoto Co.") (TSE: 28...

5 months ago - PRNewsWire

Essential Japanese Semi Companies For The Reshoring Age

The global COVID-19 pandemic has led to a shift towards reshoring in the semiconductor industry as supply chains are disrupted and geopolitical tensions rise. Reshoring efforts are leading to increase...

7 months ago - Seeking Alpha

Seviroli Foods Acquires a Portfolio of Italian Food Products from Ajinomoto Foods North America

GARDEN CITY, N.Y.--(BUSINESS WIRE)--Seviroli Foods LLC (“Seviroli”), a portfolio company of Mill Point Capital LLC (“Mill Point”) and a leading manufacturer of frozen pasta and other food products and...

7 months ago - Business Wire

Ajinomoto: Food, Biotech, And Semis All-In-One

Ajinomoto is diversifying its revenue segments, particularly in the biopharma and semiconductor industries, for organic growth opportunities. The company has a leading market position, high R&D invest...

10 months ago - Seeking Alpha

Ajinomoto Co., Inc. to Acquire Forge Biologics for $620 Million1

COLUMBUS, Ohio--(BUSINESS WIRE)--Ajinomoto Co., Inc. ("Ajinomoto Co."; TYO: 2802) and Forge Biologics (Forge), announced today that they have entered into a definitive agreement by which Ajinomoto Co....

10 months ago - Business Wire

Ajinomoto May Build New Factory for Chip Film

Ajinomoto says it may build an additional manufacturing base to produce more of its signature chipmaking film. Aside from its seasonings and food products, the Japanese firm also makes the Ajinomoto B...

1 year ago - Bloomberg Markets and Finance

Ajinomoto Bio-Pharma Services Successfully Develops Highly Functional Ancestral RNA Ligase

TOKYO , Feb. 22, 2023 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce ...

1 year ago - PRNewsWire

Ajinomoto and Exelixis Enter Into a License Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer

TOKYO , Jan. 10, 2023 /PRNewswire/ -- Ajinomoto Co., Inc. ("Ajinomoto Co.") today announced a license agreement with Exelixis, Inc. ("Exelixis") to incorporate AJICAP®, Ajinomoto Co.'s proprietary sit...

1 year ago - PRNewsWire